215 related articles for article (PubMed ID: 11966671)
1. Pharmacokinetics and metabolism of oral midazolam in preterm infants.
de Wildt SN; Kearns GL; Hop WC; Murry DJ; Abdel-Rahman SM; van den Anker JN
Br J Clin Pharmacol; 2002 Apr; 53(4):390-2. PubMed ID: 11966671
[TBL] [Abstract][Full Text] [Related]
2. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.
Backman JT; Kivistö KT; Olkkola KT; Neuvonen PJ
Eur J Clin Pharmacol; 1998 Mar; 54(1):53-8. PubMed ID: 9591931
[TBL] [Abstract][Full Text] [Related]
3. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.
Wandel C; Witte JS; Hall JM; Stein CM; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 2000 Jul; 68(1):82-91. PubMed ID: 10945319
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and metabolism of intravenous midazolam in preterm infants.
de Wildt SN; Kearns GL; Hop WC; Murry DJ; Abdel-Rahman SM; van den Anker JN
Clin Pharmacol Ther; 2001 Dec; 70(6):525-31. PubMed ID: 11753268
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.
de Wildt SN; de Hoog M; Vinks AA; van der Giesen E; van den Anker JN
Crit Care Med; 2003 Jul; 31(7):1952-8. PubMed ID: 12847388
[TBL] [Abstract][Full Text] [Related]
6. Single plasma sampling to predict oral clearance of CYP3A probe midazolam.
Zhu B; Ou-Yang DS; Cheng ZN; Huang SL; Zhou HH
Acta Pharmacol Sin; 2001 Jul; 22(7):634-8. PubMed ID: 11749829
[TBL] [Abstract][Full Text] [Related]
7. The interaction between St John's wort and an oral contraceptive.
Hall SD; Wang Z; Huang SM; Hamman MA; Vasavada N; Adigun AQ; Hilligoss JK; Miller M; Gorski JC
Clin Pharmacol Ther; 2003 Dec; 74(6):525-35. PubMed ID: 14663455
[TBL] [Abstract][Full Text] [Related]
8. The effect of hormone replacement therapy on CYP3A activity.
Gorski JC; Wang Z; Haehner-Daniels BD; Wrighton SA; Hall SD
Clin Pharmacol Ther; 2000 Oct; 68(4):412-7. PubMed ID: 11061581
[TBL] [Abstract][Full Text] [Related]
9. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
Palmer JL; Scott RJ; Gibson A; Dickins M; Pleasance S
Br J Clin Pharmacol; 2001 Nov; 52(5):555-61. PubMed ID: 11736864
[TBL] [Abstract][Full Text] [Related]
10. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
11. CYP3A activity in European American and Japanese men using midazolam as an in vivo probe.
Tateishi T; Watanabe M; Nakura H; Asoh M; Shirai H; Mizorogi Y; Kobayashi S; Thummel KE; Wilkinson GR
Clin Pharmacol Ther; 2001 May; 69(5):333-9. PubMed ID: 11372001
[TBL] [Abstract][Full Text] [Related]
12. The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity.
Belle DJ; Callaghan JT; Gorski JC; Maya JF; Mousa O; Wrighton SA; Hall SD
Br J Clin Pharmacol; 2002 Jan; 53(1):67-74. PubMed ID: 11849197
[TBL] [Abstract][Full Text] [Related]
13. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
14. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
[TBL] [Abstract][Full Text] [Related]
15. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam.
Kashuba AD; Bertino JS; Rocci ML; Kulawy RW; Beck DJ; Nafziger AN
Clin Pharmacol Ther; 1998 Sep; 64(3):269-77. PubMed ID: 9757150
[TBL] [Abstract][Full Text] [Related]
16. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice.
Greenblatt DJ; von Moltke LL; Harmatz JS; Chen G; Weemhoff JL; Jen C; Kelley CJ; LeDuc BW; Zinny MA
Clin Pharmacol Ther; 2003 Aug; 74(2):121-9. PubMed ID: 12891222
[TBL] [Abstract][Full Text] [Related]
17. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study.
Hamaoka N; Oda Y; Hase I; Mizutani K; Nakamoto T; Ishizaki T; Asada A
Clin Pharmacol Ther; 1999 Aug; 66(2):110-7. PubMed ID: 10460064
[TBL] [Abstract][Full Text] [Related]
18. Midazolam and cortisol metabolism before and after CYP3A induction in humans.
Eeckhoudt SL; Desager JP; Robert AR; Leclercq I; Verbeeck RK; Horsmans Y
Int J Clin Pharmacol Ther; 2001 Jul; 39(7):293-9. PubMed ID: 11471773
[TBL] [Abstract][Full Text] [Related]
19. Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers.
Krupka E; Venisse N; Lafay C; Gendre D; Diquet B; Bouquet S; Perault MC
Eur J Clin Pharmacol; 2006 Aug; 62(8):653-9. PubMed ID: 16832678
[TBL] [Abstract][Full Text] [Related]
20. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
